ClinicalTrials.gg
CompletedNCT02198651PREDICTRAUpdated Jun 25, 2019Results posted

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

A Phase 4 interventional study of Adalimumab and Placebo in Rheumatoid Arthritis and Musculoskeletal and Connective Tissue Diseases, sponsored by AbbVie. Completed at 70 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by AbbVie · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
47th of 87
149 · median 160
Started
2015
with 7 others
Phase 4
33 of 87
1 open now
Registered
63rd of 87
by date
Lead sponsor
5 of 87
AbbVie

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 47th largest by enrollment, is one of 8 that started in 2015, is one of 33 in phase 4, and was the 63rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to an adalimumab dose tapering regimen controlled by adalimumab withdrawal.

Read the detailed description

This was a Phase 4, multicenter, randomized, double-blind, parallel-group study. The study included a Screening period of up to 28 days (unless extended with justification approved by study-designated physician), a 4-week Lead-In Period with open label (OL) 40 mg adalimumab administered subcutaneously (sc) every other week (eow), and a randomized 36-week double-blind period with 40 mg adalimumab sc every 3 weeks (q3wks; tapering arm) or placebo sc q3wks (withdrawal arm). Participants were randomized in a 5:1 ratio (tapering arm: withdrawal arm) after confirmation of meeting the disease activity score (DAS) criteria. Participants who experienced a protocol-defined flare at any time were to enter a rescue arm with OL 40 mg adalimumab administered sc eow for 16 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
  • Musculoskeletal and Connective Tissue Diseases

Keywords

  • Rheumatoid Arthritis
  • Adalimumab
  • Taper
  • Flare
  • Arthritis
  • Anti-rheumatic drugs
  • Remission
  • Magnetic Resonance Imaging
  • Ultrasound
  • Biomarker
  • Drug Level
  • Reduced dose
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant had a diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR /European League Against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis).
  2. Participant must have met the following criteria:

    • Must have been treated with adalimumab 40 mg subcutaneously every other week (sc eow) for at least 12 months prior to Week 0 Visit
    • Must have been treated with concomitant methotrexate (MTX) at a stable dose (oral, sc or intramuscular (im) at any dose) for at least 12 weeks prior to Week 0 Visit or if not on MTX, must have been treated with other allowed conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) at a stable dose for at least 12 weeks prior to Week 0 Visit or if not treated with csDMARDs must maintain this regimen for at least 12 weeks prior to Week 0 Visit.
  3. Participant must be in sustained clinical remission based on the following:

    • At least one documented 4 or 3 (if Patient's Global Assessment ; PGA is not available) variables Disease Activity Score 28 Erythrocyte sedimentation rate (DAS28 ESR) or DAS28 C-reactive protein (CRP) \< 2.6 (or calculated based on documented components of the DAS28) in the participant's chart 6 months or longer prior to the Screening Visit;
    • 4 variables DAS28 (ESR) assessed at Screening \< 2.6, with all components including ESR assessed at Screening.
  4. If participant was receiving concomitant allowed csDMARDs (in addition or not to MTX) the dose must have been stable for at least 12 weeks prior to the Week 0 Visit (e.g., chloroquine, hydroxychloroquine, sulfasalazine, gold formulations [including auranofin, gold sodium thiomalate, and aurothioglucose] and/or leflunomide).
  5. If participant was receiving concomitant oral , prednisone or equivalent must have been \< 10 mg/day and the dose must have been stable for at least 4 weeks prior to the Week 0 Visit.
  6. If participant was receiving concomitant non-steroidal anti-inflammatory drugs (NSAIDs), tramadol or other equivalent opioids and/or non-opioid analgesics, the dose and/or therapeutic scheme must have been stable for at least 4 weeks prior to the Week 0 Visit.
  7. Participant must have been able and willing to provide written and comply with the requirements of this study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Any 4 or 3 (if PGA is not available) variables DAS28 (ESR) or DAS28 (CRP) (or calculated based on documented components of the DAS28) assessed within 6 months prior to the Screening Visit ≥ 2.6.
  2. Participant was on an additional concomitant biological disease-modifying anti-rheumatic drug (bDMARD) (including but not limited to abatacept, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab).
  3. Participant had been treated with intra-articular or parenteral within the last four weeks before Screening.
  4. Participant had undergone joint surgery within 12 weeks of Screening (at joints to be assessed by magnetic resonance imaging (MRI) and/or ultrasound).
  5. Participant had a medical condition precluding an MRI (e.g. magnetic activated implanted devices - cardiac pace-maker, insulin pump, neuro stimulators, etc. and metallic devices or fragments or clips in the eye, brain or spinal canal and in the hand/wrist undergoing MRI)
  6. Participant had a medical condition precluding a contrast MRI with gadolinium [e.g. nephrogenic systemic fibrosis, previous anaphylactic/anaphylactoid reaction to gadolinium containing contrast agent, pregnancy or breast feeding, severe renal insufficiency with an estimated (eGFR) below 30 mL/min/1.73m\^2 at Screening, hepato-renal syndrome, severe chronic liver function impairment]
  7. Participant had been treated with any drug of chemical or biologic nature within a minimum of 30 days or five half-lives (whichever is longer) of the drug prior to the Screening Visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Adalimumab 40 mg eow

    40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)

    Biological: Adalimumab

  • Active comparator
    Adalimumab Tapering

    40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)

    Biological: Adalimumab

  • Placebo comparator
    Adalimumab Withdrawal Arm

    Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)

    Other: Placebo

  • Experimental
    Adalimumab 40 mg eow Rescue Arm

    40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Pre-filled syringe, administered by subcutaneous injection

    Also known as: ABT-D2E7, Humira

  • OtherPlacebo

    Pre-filled syringe, administered by subcutaneous injection in the Double-blind period

06

What researchers measure

Primary outcomes

  1. Association Between Baseline Hand and Wrist Synovitis Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score and Flare up to Week 40 in the Tapering Arm

    Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline hand and wrist synovitis RAMRIS score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.

    Time frame: From Week 4 to Week 40

  2. Association Between Baseline Bone Marrow Edema RAMRIS Score and Flare up to Week 40 in the Tapering Arm

    Bone marrow edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.

    Time frame: From Week 4 to Week 40

  3. Association Between a Composite of Baseline Hand and Wrist Synovitis and Bone Marrow Edema RAMRIS Scores and Flare up to Week 40 in the Tapering Arm

    The composite score is the sum of the baseline hand and wrist synovitis and bone marrow edema RAMRIS scores. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between the composite baseline hand and wrist synovitis score and baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.

    Time frame: From Week 4 to Week 40

Secondary outcomes

  1. Median Time to Flare

    Time to flare was defined as the number of weeks from the date of the first dose of study drug in the Double-blind period to the date of flare.

    Time frame: From Week 4 to Week 40

  2. Physicians' Assessment of Flare Severity

    Physicians rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.

    Time frame: At the Flare Week 0 Visit

  3. Participants' Assessment of Flare Severity

    Participants rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.

    Time frame: At the Flare Week 0 Visit

  4. Percentage of Participants With a Flare

    Flare was defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\].

    Time frame: From Week 4 to Week 40

  5. Number of Participants Who Regained Clinical Remission in the Open-Label Rescue Arm Over Time

    The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6.

    Time frame: From Flare Week 0 to Flare Week 16

  6. Median Time to Clinical Remission From the Occurrence of Flare

    The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6. Time to clinical remission was defined as the number of weeks from the occurrence of flare to the first date of clinical remission.

    Time frame: From Flare Week 0 to Flare Week 16

  7. Mean Change From Double-blind Baseline in Disease Activity Score 28 (DAS28)

    The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  8. Mean Change From Double-blind Baseline in Clinical Disease Activity Index (CDAI) Score

    The CDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), and global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm) were included in the CDAI score. Scores on the CDAI range from 0 to 76; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  9. Mean Change From Double-blind Baseline in Simplified Disease Activity Index (SDAI) Score

    The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein levels (mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  10. Number of Participants Maintaining Clinical Remission Defined By DAS28 (ESR) < 2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8 at Each Visit By Treatment Arm

    The maintenance of clinical remission after regaining remission during the Open-label rescue period was defined as either Disease Activity Score 28 (DAS28 ESR) \< 2.6, Simplified Disease Activity Index (SDAI) score ≤ 3.3, or Clinical Disease Activity Index (CDAI) score ≤ 2.8).

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  11. Mean Change From Double-blind Baseline to Week 40 or Final Visit in Magnetic Resonance Imaging (MRI) Synovitis Score

    Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.

    Time frame: From Week 4 to Week 40 or Final visit

  12. Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Marrow Edema (BME) Score

    Bone edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%.

    Time frame: From Week 4 to Week 40 or Final visit

  13. Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Erosions Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score

    Bone erosions in each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) were scored separately. The scale is 0-10, based on the proportion of eroded bone compared to the ''assessed bone volume'', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2; 11-20%, etc.

    Time frame: From Week 4 to Week 40 or Final Visit

  14. Mean Change From Double-blind Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score Over Time

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥ 0.22.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  15. Number of Participants With Health Assessment Questionnaire- Disability Index (HAQ-DI) Score ≤ 0.5 at Double-blind Baseline and at Week 40

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The number of participants with HAQ-DI score ≤ 0.5 (considered to be normal) was recorded.

    Time frame: Week 4 and Week 40

  16. Mean Change From Double-blind Baseline in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed During In-office Visits

    The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  17. Mean Change From Flare Week 0 in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed at Home

    The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.

    Time frame: Flare Week 0 and Flare Weeks 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15

  18. Mean Change From Double-blind Baseline in Swollen Joint Count 28

    Twenty-eight joints, excluding hip joints, were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 28 (worst possible score/28 joints with swelling). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  19. Mean Change From Double-blind Baseline in Swollen Joint Count 66

    Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  20. Mean Change From Double-blind Baseline in Tender Joint Count 28

    Twenty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 28 (worst possible score/28 joints with tenderness). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  21. Mean Change From Double-blind Baseline in Tender Joint Count 68

    Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  22. Mean Change From Double-blind Baseline in Participant's Global Assessment of Disease Activity

    Participants rated the severity of their rheumatoid arthritis symptoms and how well they were doing during the last 24 hours by placing a vertical mark on a line with a range of 0 (very well) to 100 mm (very poorly). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  23. Mean Change From Double-blind Baseline in Participant's Global Assessment of Rheumatoid Arthritis Pain

    Participants rated the severity of their rheumatoid arthritis pain in the past week by placing a vertical mark on a line with a range of 0 (no pain) to 100 mm (severe pain). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  24. Mean Change From Double-blind Baseline in Physician's Global Assessment of Disease Activity

    Physicians assessed participants' current rheumatoid arthritis disease activity at the time of the visit (independent of the participant's self-assessment) by placing a vertical mark on a line with a range of 0 (very low) to 100 mm (very high). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  25. Mean Change From Double-blind Baseline in Morning Stiffness Duration

    The duration of morning stiffness was reported by participants as the average daily length during the past week in minutes (from time of awaking to time of maximal improvement). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  26. Mean Change From Double-blind Baseline in Morning Stiffness Severity

    Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  27. Mean Change From Double-blind Baseline in Participant's Assessment of Sleep Disturbance

    Participants rated the severity of their sleep disturbance in the past week by placing a vertical mark on a line with a range of 0 (sleep is no problem) to 100 mm (sleep is a major problem). Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  28. Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Effectiveness Score

    Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

    Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16

  29. Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Side Effects Score

    Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

    Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16

  30. Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Convenience Score

    Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

    Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16

  31. Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score

    Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

    Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16

  32. Mean Change From Double-blind Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment and Activity Impairment Scores

    The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in rheumatoid arthritis consisting of 6 questions, based on participant recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

    Time frame: At Weeks 4, 28, and 40 and Flare Weeks 0, 10, and 16

  33. Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Physical Component Summary (PCS) Score

    The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.

    Time frame: At Weeks 4, 28, and 40 and from Flare Week 0 to Flare Week 16

  34. Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Mental Component Summary (MCS) Score

    The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.

    Time frame: At Weeks 4, 28, and 40 and from Flare Week 0 to Flare Week 16

  35. Mean Change From Double-blind Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale

    The FACIT-Fatigue questionnaire is a participant questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A negative change from baseline indicates worsening.

    Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16

  36. Mean Change From Double-blind Baseline in Serum Levels of C-reactive Protein (CRP)

    C-Reactive Protein (CRP; mg/L) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

  37. Mean Change From Double-blind Baseline in Serum Levels of Erythrocyte Sedimentation Rate (ESR)

    Erythrocyte sedimentation rate (ESR; mm/hour) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. Negative values indicate improvement from baseline.

    Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16

07

Results

Posted Jun 25, 2019

Participant flow

Lead-in Period
Participant flow — Lead-in Period
MilestoneAdalimumab 40 mg EowAdalimumab TaperingAdalimumab Withdrawal ArmAdalimumab Tapering to Rescue ArmAdalimumab Withdrawal to Rescue Arm
Started1490000
Participants treated in lead-in period1460000
Completed1120000
Not completed370000
Withdrew: Withdrew consent130000
Withdrew: Adverse event20000
Withdrew: Other, not specified220000
Double-blind Period
Participant flow — Double-blind Period
MilestoneAdalimumab 40 mg EowAdalimumab TaperingAdalimumab Withdrawal ArmAdalimumab Tapering to Rescue ArmAdalimumab Withdrawal to Rescue Arm
Started01022000
Completed0931900
Not completed09100
Withdrew: Withdrew consent04000
Withdrew: Adverse event01000
Withdrew: Other, not specified04100
Open-label Rescue Period
Participant flow — Open-label Rescue Period
MilestoneAdalimumab 40 mg EowAdalimumab TaperingAdalimumab Withdrawal ArmAdalimumab Tapering to Rescue ArmAdalimumab Withdrawal to Rescue Arm
Started000318
Correctly entered open-label rescue000308
Completed000288
Not completed00030
Withdrew: Withdrew consent00020
Withdrew: Incorrectly entered open-label rescue00010

Outcome measures

PrimaryAssociation Between Baseline Hand and Wrist Synovitis Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score and Flare up to Week 40 in the Tapering Arm

Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline hand and wrist synovitis RAMRIS score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.

Time frame:
From Week 4 to Week 40
Reported as:
Number · odds ratio
Association Between Baseline Hand and Wrist Synovitis Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score and Flare up to Week 40 in the Tapering Arm
odds ratioAdalimumab Tapering
Association Between Baseline Hand and Wrist Synovitis Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score and Flare up to Week 40 in the Tapering Arm0.993 (0.822 to 1.199)
Statistical analysis
  • Adalimumab Tapering · Wald Chi · p = 0.943
PrimaryAssociation Between Baseline Bone Marrow Edema RAMRIS Score and Flare up to Week 40 in the Tapering Arm

Bone marrow edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.

Time frame:
From Week 4 to Week 40
Reported as:
Number · odds ratio
Association Between Baseline Bone Marrow Edema RAMRIS Score and Flare up to Week 40 in the Tapering Arm
odds ratioAdalimumab Tapering
Association Between Baseline Bone Marrow Edema RAMRIS Score and Flare up to Week 40 in the Tapering Arm0.959 (0.821 to 1.119)
Statistical analysis
  • Adalimumab Tapering · Wald Chi · p = 0.592
PrimaryAssociation Between a Composite of Baseline Hand and Wrist Synovitis and Bone Marrow Edema RAMRIS Scores and Flare up to Week 40 in the Tapering Arm

The composite score is the sum of the baseline hand and wrist synovitis and bone marrow edema RAMRIS scores. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between the composite baseline hand and wrist synovitis score and baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.

Time frame:
From Week 4 to Week 40
Reported as:
Number · odds ratio
Association Between a Composite of Baseline Hand and Wrist Synovitis and Bone Marrow Edema RAMRIS Scores and Flare up to Week 40 in the Tapering Arm
odds ratioAdalimumab Tapering
Association Between a Composite of Baseline Hand and Wrist Synovitis and Bone Marrow Edema RAMRIS Scores and Flare up to Week 40 in the Tapering Arm0.979 (0.885 to 1.084)
Statistical analysis
  • Adalimumab Tapering · Wald Chi · p = 0.688
SecondaryMedian Time to Flare

Time to flare was defined as the number of weeks from the date of the first dose of study drug in the Double-blind period to the date of flare.

Time frame:
From Week 4 to Week 40
Reported as:
Median · weeks
Median Time to Flare
weeksAdalimumab TaperingAdalimumab Withdrawal Arm
Median Time to FlareNA (36.4 to NA)NA (12.1 to NA)
SecondaryPhysicians' Assessment of Flare Severity

Physicians rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.

Time frame:
At the Flare Week 0 Visit
Reported as:
Count of participants · Participants
Physicians' Assessment of Flare Severity
ParticipantsAdalimumab TaperingAdalimumab Withdrawal Arm
011
120
230
331
462
511
640
710
800
900
1000
Missing93
SecondaryParticipants' Assessment of Flare Severity

Participants rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.

Time frame:
At the Flare Week 0 Visit
Reported as:
Count of participants · Participants
Participants' Assessment of Flare Severity
ParticipantsAdalimumab TaperingAdalimumab Withdrawal Arm
010
121
222
330
440
511
641
710
820
900
1020
Missing83
SecondaryPercentage of Participants With a Flare

Flare was defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\].

Time frame:
From Week 4 to Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With a Flare
percentage of participantsAdalimumab TaperingAdalimumab Withdrawal Arm
Percentage of Participants With a Flare36.3 (27.0 to 46.4)45.0 (23.1 to 68.5)
SecondaryNumber of Participants Who Regained Clinical Remission in the Open-Label Rescue Arm Over Time

The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6.

Time frame:
From Flare Week 0 to Flare Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Regained Clinical Remission in the Open-Label Rescue Arm Over Time
ParticipantsAdalimumab TaperingAdalimumab Withdrawal Arm
Flare Week 031
Flare Week 4141
Flare Week 10173
Flare Week 16134
SecondaryMedian Time to Clinical Remission From the Occurrence of Flare

The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6. Time to clinical remission was defined as the number of weeks from the occurrence of flare to the first date of clinical remission.

Time frame:
From Flare Week 0 to Flare Week 16
Reported as:
Median · weeks
Median Time to Clinical Remission From the Occurrence of Flare
weeksAdalimumab TaperingAdalimumab Withdrawal Arm
Median Time to Clinical Remission From the Occurrence of Flare6.1 (4.1 to 16.3)18.0 (0.1 to 18.0)
SecondaryMean Change From Double-blind Baseline in Disease Activity Score 28 (DAS28)

The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Disease Activity Score 28 (DAS28)
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm0.7 ± 1.270.1 ± 0.46
Double Blind Week 10- Withdrawal Arm0.1 ± 0.470.1 ± 0.55
Double Blind Week 16- Tapering Arm1.2 ± 1.340.1 ± 0.39
Double Blind Week 16- Withdrawal Arm0.9 ± 0.580.0 ± 0.43
Double Blind Week 22- Tapering Arm0.7 ± 1.18-0.0 ± 0.53
Double Blind Week 22- Withdrawal Arm0.5 ± 0.310.1 ± 0.24
Double Blind Week 28- Tapering arm0.8 ± 1.160.1 ± 0.50
Double Blind Week 28- Withdrawal arm1.0 ± 1.540.2 ± 0.25
Double Blind Week 34- Tapering Arm0.7 ± 0.59-0.0 ± 0.54
Double Blind Week 34- Withdrawal Arm-0.7 ± 0.11-0.0 ± 0.46
Double Blind Week 40- Tapering Arm1.5 ± 1.200.0 ± 0.52
Double Blind Week 40- Withdrawal Arm0.8 ± 2.180.2 ± 0.38
Flare Week 0- Tapering Arm2.3 ± 1.15—
Flare Week 0- Withdrawal Arm1.9 ± 0.96—
Flare Week 4- Tapering Arm1.3 ± 1.05—
Flare Week 4- Withdrawal Arm1.2 ± 1.14—
Flare Week 10- Tapering Arm0.9 ± 0.81—
Flare Week 10- Withdrawal Arm0.7 ± 0.50—
Flare Week 16- Tapering Arm1.2 ± 1.04—
Flare Week 16- Withdrawal Arm0.6 ± 0.80—
SecondaryMean Change From Double-blind Baseline in Clinical Disease Activity Index (CDAI) Score

The CDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), and global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm) were included in the CDAI score. Scores on the CDAI range from 0 to 76; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Clinical Disease Activity Index (CDAI) Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm4.4 ± 7.680.6 ± 1.34
Double Blind Week 10- Withdrawal Arm1.0 ± 2.451.4 ± 2.85
Double Blind Week 16- Tapering Arm7.0 ± 9.350.4 ± 1.30
Double Blind Week 16- Withdrawal Arm2.9 ± 2.42-0.1 ± 0.88
Double Blind Week 22- Tapering Arm3.2 ± 4.980.3 ± 1.38
Double Blind Week 22- Withdrawal Arm2.2 ± 1.930.1 ± 0.73
Double Blind Week 28- Tapering arm3.7 ± 6.190.5 ± 1.37
Double Blind Week 28- Withdrawal arm6.3 ± 8.40-0.1 ± 0.80
Double Blind Week 34- Tapering Arm2.7 ± 3.040.2 ± 1.08
Double Blind Week 34- Withdrawal Arm-0.1 ± 0.140.0 ± 0.92
Double Blind Week 40- Tapering Arm7.4 ± 10.040.1 ± 1.33
Double Blind Week 40- Withdrawal Arm7.7 ± 11.38-0.3 ± 0.48
Flare Week 0- Tapering Arm12.3 ± 9.56—
Flare Week 0- Withdrawal Arm9.4 ± 9.13—
Flare Week 4- Tapering Arm5.0 ± 6.55—
Flare Week 4- Withdrawal Arm5.4 ± 9.59—
Flare Week 10- Tapering Arm3.5 ± 4.55—
Flare Week 10- Withdrawal Arm3.6 ± 2.52—
Flare Week 16- Tapering Arm4.5 ± 6.14—
Flare Week 16- Withdrawal Arm2.8 ± 4.19—
SecondaryMean Change From Double-blind Baseline in Simplified Disease Activity Index (SDAI) Score

The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein levels (mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Simplified Disease Activity Index (SDAI) Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm3.7 ± 8.570.8 ± 1.85
Double Blind Week 10- Withdrawal Arm0.9 ± 2.591.3 ± 2.67
Double Blind Week 16- Tapering Arm6.3 ± 10.250.4 ± 1.35
Double Blind Week 16- Withdrawal Arm3.6 ± 2.80-0.1 ± 0.90
Double Blind Week 22- Tapering Arm3.6 ± 5.180.3 ± 1.47
Double Blind Week 22- Withdrawal Arm2.3 ± 1.95-0.0 ± 0.88
Double Blind Week 28- Tapering arm3.8 ± 6.340.4 ± 1.37
Double Blind Week 28- Withdrawal arm6.4 ± 8.400.1 ± 1.61
Double Blind Week 34- Tapering Arm3.0 ± 3.290.2 ± 1.17
Double Blind Week 34- Withdrawal Arm0.1 ± 0.330.1 ± 1.07
Double Blind Week 40- Tapering Arm7.5 ± 10.270.1 ± 1.37
Double Blind Week 40- Withdrawal Arm8.5 ± 10.23-0.3 ± 0.62
Flare Week 0- Tapering Arm11.6 ± 11.17—
Flare Week 0- Withdrawal Arm9.9 ± 8.31—
Flare Week 4- Tapering Arm4.1 ± 8.73—
Flare Week 4- Withdrawal Arm5.2 ± 9.64—
Flare Week 10- Tapering Arm2.5 ± 7.53—
Flare Week 10- Withdrawal Arm3.5 ± 2.51—
Flare Week 16- Tapering Arm3.6 ± 6.63—
Flare Week 16- Withdrawal Arm2.7 ± 4.20—
SecondaryNumber of Participants Maintaining Clinical Remission Defined By DAS28 (ESR) < 2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8 at Each Visit By Treatment Arm

The maintenance of clinical remission after regaining remission during the Open-label rescue period was defined as either Disease Activity Score 28 (DAS28 ESR) \< 2.6, Simplified Disease Activity Index (SDAI) score ≤ 3.3, or Clinical Disease Activity Index (CDAI) score ≤ 2.8).

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Count of participants · Participants
Number of Participants Maintaining Clinical Remission Defined By DAS28 (ESR) < 2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8 at Each Visit By Treatment Arm
ParticipantsDAS28 (ESR) < 2.6SDAI ≤ 3.3CDAI ≤ 2.8
Double Blind Baseline- Tapering Arm1028985
Double Blind Baseline- Withdrawal Arm201919
Double Blind Week 10- Tapering Arm856362
Double Blind Week 10- Withdrawal Arm181614
Double Blind Week 16- Tapering Arm786462
Double Blind Week 16- Withdrawal arm151315
Double Blind Week 22- Tapering Arm755958
Double Blind Week 22- Withdrawal Arm141313
Double Blind Week 28- Tapering Arm695857
Double Blind Week 28- Withdrawal Arm131213
Double Blind Week 34- Tapering Arm705858
Double Blind Week 34- Withdrawal Arm131313
Double Blind Week 40- Tapering Arm645756
Double Blind Week 40- Withdrawal Arm111212
Flare Week 0- Tapering Arm444
Flare Week 0- Withdrawal Arm102
Flare Week 4- Tapering Arm141313
Flare Week 4- Withdrawal Arm122
Flare Week 10- Tapering Arm171414
Flare Week 10- Withdrawal Arm322
Flare Week 16- Tapering Arm131313
Flare Week 16- Withdrawal Arm444
SecondaryMean Change From Double-blind Baseline to Week 40 or Final Visit in Magnetic Resonance Imaging (MRI) Synovitis Score

Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.

Time frame:
From Week 4 to Week 40 or Final visit
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline to Week 40 or Final Visit in Magnetic Resonance Imaging (MRI) Synovitis Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 40- Tapering Arm-0.1 ± 1.200.1 ± 1.33
Double Blind Week 40- Withdrawal Arm0.0-0.1 ± 0.90
Flare Week 16- Tapering Arm0.8 ± 1.84—
Flare Week 16- Withdrawal Arm0.1 ± 1.81—
SecondaryMean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Marrow Edema (BME) Score

Bone edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%.

Time frame:
From Week 4 to Week 40 or Final visit
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Marrow Edema (BME) Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 40- Tapering Arm-0.5 ± 0.840.0 ± 1.07
Double Blind Week 40- Withdrawal Arm0.01.2 ± 3.52
Flare Week 16- Tapering Arm-0.1 ± 0.47—
Flare Week 16- Withdrawal Arm0.3 ± 0.38—
SecondaryMean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Erosions Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score

Bone erosions in each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) were scored separately. The scale is 0-10, based on the proportion of eroded bone compared to the ''assessed bone volume'', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2; 11-20%, etc.

Time frame:
From Week 4 to Week 40 or Final Visit
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Erosions Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 40- Tapering Arm-0.5 ± 1.730.1 ± 0.52
Double Blind Week 40- Withdrawal Arm-2.00.0 ± 1.08
Flare Week 16- Tapering Arm0.3 ± 1.02—
Flare Week 16- Withdrawal Arm0.1 ± 0.88—
SecondaryMean Change From Double-blind Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score Over Time

The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥ 0.22.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score Over Time
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm0.1 ± 0.30.0 ± 0.18
Double Blind Week 10- Withdrawal Arm0.3 ± 0.610.0 ± 0.17
Double Blind Week 16- Tapering Arm0.2 ± 0.40-0.0 ± 0.28
Double Blind Week 16- Withdrawal Arm0.3 ± 0.54-0.0 ± 0.12
Double Blind Week 22- Tapering Arm0.1 ± 0.37-0.0 ± 0.26
Double Blind Week 22- Withdrawal Arm0.4 ± 0.790.1 ± 0.39
Double Blind Week 28- Tapering Arm0.2 ± 0.43-0.0 ± 0.27
Double Blind Week 28- Withdrawal Arm0.7 ± 0.69-0.1 ± 0.15
Double Blind Week 34- Tapering Arm0.3 ± 0.49-0.0 ± 0.30
Double Blind Week 34- Withdrawal Arm0.2 ± 0.270.1 ± 0.17
Double Blind Week 40- Tapering Arm0.4 ± 0.40-0.1 ± 0.33
Double Blind Week 40- Withdrawal Arm1.90.0 ± 0.16
Flare Week 0- Tapering Arm0.4 ± 0.57—
Flare Week 0- Withdrawal Arm0.3 ± 0.29—
Flare Week 4- Tapering Arm0.2 ± 0.49—
Flare Week 4- Withdrawal Arm0.2 ± 0.35—
Flare Week 10- Tapering Arm0.1 ± 0.24—
Flare Week 10- Withdrawal Arm0.1 ± 0.20—
Flare Week 16- Tapering Arm0.2 ± 0.39—
Flare Week 16- Withdrawal Arm0.1 ± 0.24—
SecondaryNumber of Participants With Health Assessment Questionnaire- Disability Index (HAQ-DI) Score ≤ 0.5 at Double-blind Baseline and at Week 40

The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The number of participants with HAQ-DI score ≤ 0.5 (considered to be normal) was recorded.

Time frame:
Week 4 and Week 40
Reported as:
Count of participants · Participants
Number of Participants With Health Assessment Questionnaire- Disability Index (HAQ-DI) Score ≤ 0.5 at Double-blind Baseline and at Week 40
ParticipantsFlared ParticipantsNon-Flared Participants
Double Blind Week 4- Tapering Arm2150
Double Blind Week 4- Withdrawal Arm710
Double Blind Week 40- Tapering Arm248
Double Blind Week 40- Withdrawal Arm09
SecondaryMean Change From Double-blind Baseline in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed During In-office Visits

The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed During In-office Visits
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm1.9 ± 3.920.7 ± 3.20
Double Blind Week 10- Withdrawal Arm1.4 ± 3.731.5 ± 4.67
Double Blind Week 16- Tapering Arm4.7 ± 5.660.8 ± 2.80
Double Blind Week 16- Withdrawal Arm2.5 ± 4.590.1 ± 1.37
Double Blind Week 22- Tapering Arm2.6 ± 4.830.3 ± 2.83
Double Blind Week 22- Withdrawal arm3.6 ± 4.180.6 ± 3.31
Double Blind Week 28- Tapering arm2.2 ± 4.200.6 ± 2.47
Double Blind Week 28- Withdrawal Arm3.7 ± 4.45-0.3 ± 1.61
Double Blind Week 34- Tapering Arm2.2 ± 3.77-0.0 ± 1.93
Double Blind Week 34- Withdrawal Arm1.9 ± 2.621.6 ± 2.33
Double Blind Week 40- Tapering Arm4.7 ± 6.220.0 ± 2.39
Double Blind Week 40- Withdrawal Arm0.4 ± 0.920.8 ± 1.62
Flare Week 0- Tapering Arm6.1 ± 6.64—
Flare Week 0- Withdrawal Arm3.9 ± 5.60—
Flare Week 4- Tapering Arm3.1 ± 5.38—
Flare Week 4- Withdrawal Arm3.2 ± 4.15—
Flare Week 10- Tapering Arm2.8 ± 3.93—
Flare Week 10- Withdrawal Arm2.3 ± 2.61—
Flare Week 16- Tapering Arm2.9 ± 4.22—
Flare Week 16- Withdrawal Arm2.1 ± 3.01—
SecondaryMean Change From Flare Week 0 in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed at Home

The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.

Time frame:
Flare Week 0 and Flare Weeks 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15
Reported as:
Mean · units on a scale
Mean Change From Flare Week 0 in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed at Home
units on a scaleFlared Participants
Flare Week 1- Tapering Arm-1.6 ± 4.92
Flare Week 1- Withdrawal Arm3.7 ± 7.20
Flare Week 2- Tapering Arm-3.1 ± 5.41
Flare Week 2- Withdrawal Arm0.8 ± 6.89
Flare Week 3- Tapering Arm-3.8 ± 6.78
Flare Week 3- Withdrawal Arm-0.4 ± 7.94
Flare Week 5- Tapering Arm-3.8 ± 6.61
Flare Week 5- Withdrawal Arm-0.8 ± 6.56
Flare Week 6- Tapering Arm-4.1 ± 6.81
Flare Week 6- Withdrawal Arm-0.9 ± 6.97
Flare Week 7- Tapering Arm-3.7 ± 6.86
Flare Week 7- Withdrawal Arm-0.6 ± 6.26
Flare Week 8- Tapering Arm-4.4 ± 7.17
Flare Week 8- Withdrawal Arm-0.6 ± 5.56
Flare Week 9- Tapering Arm-3.3 ± 5.81
Flare Week 9- Withdrawal Arm-1.0 ± 5.89
Flare Week 11- Tapering Arm-3.7 ± 5.69
Flare Week 11- Withdrawal Arm-1.0 ± 5.85
Flare Week 12- Tapering Arm-3.4 ± 5.84
Flare Week 12- Withdrawal Arm-2.3 ± 4.46
Flare Week 13- Tapering Arm-3.5 ± 5.72
Flare Week 13- Withdrawal Arm-2.5 ± 4.78
Flare Week 14- Tapering Arm-3.1 ± 5.54
Flare Week 14- Withdrawal Arm-2.4 ± 4.79
Flare Week 15- Tapering Arm-3.5 ± 6.69
Flare Week 15- Withdrawal Arm-2.2 ± 4.70
SecondaryMean Change From Double-blind Baseline in Swollen Joint Count 28

Twenty-eight joints, excluding hip joints, were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 28 (worst possible score/28 joints with swelling). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · swollen joint counts
Mean Change From Double-blind Baseline in Swollen Joint Count 28
swollen joint countsFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm0.9 ± 2.090.1 ± 0.58
Double Blind Week 10- Withdrawal Arm0.1 ± 0.33-0.1 ± 0.30
Double Blind Week 16- Tapering Arm1.2 ± 2.15-0.0 ± 0.34
Double Blind Week 16- Withdrawal Arm0.3 ± 0.500.0 ± 0.45
Double Blind Week 22- Tapering Arm0.6 ± 1.640.1 ± 0.64
Double Blind Week 22- Withdrawal arm0.5 ± 0.58-0.1 ± 0.30
Double Blind Week 28- Tapering arm0.5 ± 0.890.0 ± 0.33
Double Blind Week 28- Withdrawal Arm2.0 ± 2.45-0.1 ± 0.30
Double Blind Week 34- Tapering Arm0.0 ± 0.430.0 ± 0.46
Double Blind Week 34- Withdrawal Arm0.0 ± 0.00-0.1 ± 0.30
Double Blind Week 40- Tapering Arm1.5 ± 3.010.0 ± 0.42
Double Blind Week 40- Withdrawal Arm2.0 ± 2.83-0.1 ± 0.30
Flare Week 0- Tapering Arm2.3 ± 2.60—
Flare Week 0- Withdrawal Arm1.9 ± 2.10—
Flare Week 4- Tapering Arm1.2 ± 1.98—
Flare Week 4- Withdrawal Arm0.6 ± 1.06—
Flare Week 10- Tapering Arm0.4 ± 0.89—
Flare Week 10- Withdrawal Arm0.1 ± 0.35—
Flare Week 16- Tapering Arm0.9 ± 1.81—
Flare Week 16- Withdrawal Arm0.3 ± 0.46—
SecondaryMean Change From Double-blind Baseline in Swollen Joint Count 66

Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · swollen joint counts
Mean Change From Double-blind Baseline in Swollen Joint Count 66
swollen joint countsFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm1.1 ± 2.360.1 ± 0.67
Double Blind Week 10- Withdrawal Arm0.1 ± 0.33-0.2 ± 0.40
Double Blind Week 16- Tapering Arm1.4 ± 2.56-0.0 ± 0.34
Double Blind Week 16- Withdrawal Arm0.4 ± 0.530.0 ± 0.45
Double Blind Week 22- Tapering Arm0.6 ± 1.640.1 ± 0.73
Double Blind Week 22- Withdrawal arm1.0 ± 1.41-0.1 ± 0.30
Double Blind Week 28- Tapering arm0.5 ± 0.890.1 ± 0.66
Double Blind Week 28- Withdrawal Arm3.3 ± 4.72-0.2 ± 0.40
Double Blind Week 34- Tapering Arm0.0 ± 0.430.0 ± 0.54
Double Blind Week 34- Withdrawal Arm0.0 ± 0.00-0.2 ± 0.40
Double Blind Week 40- Tapering Arm1.5 ± 3.010.0 ± 0.46
Double Blind Week 40- Withdrawal Arm2.0 ± 2.83-0.2 ± 0.40
Flare Week 0- Tapering Arm2.6 ± 2.90—
Flare Week 0- Withdrawal Arm2.6 ± 3.38—
Flare Week 4- Tapering Arm1.3 ± 1.99—
Flare Week 4- Withdrawal Arm0.6 ± 1.06—
Flare Week 10- Tapering Arm0.6 ± 1.10—
Flare Week 10- Withdrawal Arm0.4 ± 0.52—
Flare Week 16- Tapering Arm1.1 ± 2.21—
Flare Week 16- Withdrawal Arm0.4 ± 0.74—
SecondaryMean Change From Double-blind Baseline in Tender Joint Count 28

Twenty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 28 (worst possible score/28 joints with tenderness). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · tender joint counts
Mean Change From Double-blind Baseline in Tender Joint Count 28
tender joint countsFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm1.3 ± 2.740.1 ± 0.54
Double Blind Week 10- Withdrawal Arm-0.1 ± 0.600.5 ± 1.21
Double Blind Week 16- Tapering Arm2.5 ± 4.490.1 ± 0.41
Double Blind Week 16- Withdrawal Arm1.0 ± 0.870.0 ± 0.00
Double Blind Week 22- Tapering Arm0.9 ± 1.66-0.0 ± 0.42
Double Blind Week 22- Withdrawal arm0.8 ± 1.500.1 ± 0.30
Double Blind Week 28- Tapering arm1.6 ± 3.390.0 ± 0.51
Double Blind Week 28- Withdrawal Arm1.8 ± 2.360.2 ± 0.40
Double Blind Week 34- Tapering Arm1.0 ± 1.65-0.0 ± 0.42
Double Blind Week 34- Withdrawal Arm0.0 ± 0.000.0 ± 0.00
Double Blind Week 40- Tapering Arm2.0 ± 2.650.0 ± 0.51
Double Blind Week 40- Withdrawal Arm3.5 ± 4.950.0 ± 0.00
Flare Week 0- Tapering Arm4.4 ± 4.63—
Flare Week 0- Withdrawal Arm3.6 ± 3.81—
Flare Week 4- Tapering Arm1.5 ± 2.27—
Flare Week 4- Withdrawal Arm2.5 ± 5.13—
Flare Week 10- Tapering Arm0.9 ± 1.84—
Flare Week 10- Withdrawal Arm1.1 ± 1.46—
Flare Week 16- Tapering Arm1.8 ± 2.64—
Flare Week 16- Withdrawal Arm1.1 ± 1.89—
SecondaryMean Change From Double-blind Baseline in Tender Joint Count 68

Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · tender joint counts
Mean Change From Double-blind Baseline in Tender Joint Count 68
tender joint countsFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm1.9 ± 3.450.3 ± 1.47
Double Blind Week 10- Withdrawal Arm0.1 ± 0.600.9 ± 1.64
Double Blind Week 16- Tapering Arm3.5 ± 6.330.2 ± 1.36
Double Blind Week 16- Withdrawal Arm1.4 ± 1.130.2 ± 0.60
Double Blind Week 22- Tapering Arm1.2 ± 2.270.2 ± 1.35
Double Blind Week 22- Withdrawal arm2.0 ± 2.830.4 ± 1.03
Double Blind Week 28- Tapering arm2.5 ± 5.340.1 ± 0.96
Double Blind Week 28- Withdrawal Arm3.8 ± 4.500.3 ± 0.47
Double Blind Week 34- Tapering Arm1.9 ± 2.870.0 ± 0.73
Double Blind Week 34- Withdrawal Arm0.0 ± 0.000.1 ± 0.30
Double Blind Week 40- Tapering Arm3.0 ± 4.240.0 ± 0.68
Double Blind Week 40- Withdrawal Arm9.0 ± 12.73-0.1 ± 0.30
Flare Week 0- Tapering Arm6.2 ± 6.93—
Flare Week 0- Withdrawal Arm6.1 ± 6.27—
Flare Week 4- Tapering Arm1.9 ± 2.50—
Flare Week 4- Withdrawal Arm4.1 ± 8.48—
Flare Week 10- Tapering Arm1.5 ± 2.69—
Flare Week 10- Withdrawal Arm2.3 ± 2.31—
Flare Week 16- Tapering Arm2.1 ± 3.37—
Flare Week 16- Withdrawal Arm1.6 ± 1.85—
SecondaryMean Change From Double-blind Baseline in Participant's Global Assessment of Disease Activity

Participants rated the severity of their rheumatoid arthritis symptoms and how well they were doing during the last 24 hours by placing a vertical mark on a line with a range of 0 (very well) to 100 mm (very poorly). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Participant's Global Assessment of Disease Activity
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm11.6 ± 19.002.6 ± 8.49
Double Blind Week 10- Withdrawal Arm8.0 ± 21.669.6 ± 20.27
Double Blind Week 16- Tapering Arm20.5 ± 26.972.4 ± 9.27
Double Blind Week 16- Withdrawal Arm10.7 ± 19.97-0.3 ± 5.76
Double Blind Week 22- Tapering Arm10.7 ± 17.741.7 ± 9.14
Double Blind Week 22- Withdrawal arm5.8 ± 8.730.2 ± 8.87
Double Blind Week 28- Tapering arm9.4 ± 21.032.7 ± 10.03
Double Blind Week 28- Withdrawal Arm15.0 ± 25.76-1.0 ± 7.82
Double Blind Week 34- Tapering Arm11.5 ± 13.701.2 ± 7.23
Double Blind Week 34- Withdrawal Arm-1.0 ± 1.410.7 ± 7.25
Double Blind Week 40- Tapering Arm22.9 ± 35.320.0 ± 7.60
Double Blind Week 40- Withdrawal Arm2.0 ± 9.90-1.7 ± 4.45
Flare Week 0- Tapering Arm29.5 ± 29.43—
Flare Week 0- Withdrawal Arm21.6 ± 27.07—
Flare Week 4- Tapering Arm13.7 ± 22.93—
Flare Week 4- Withdrawal Arm11.7 ± 21.96—
Flare Week 10- Tapering Arm11.7 ± 16.89—
Flare Week 10- Withdrawal Arm14.1 ± 10.35—
Flare Week 16- Tapering Arm9.4 ± 13.47—
Flare Week 16- Withdrawal Arm6.9 ± 9.31—
SecondaryMean Change From Double-blind Baseline in Participant's Global Assessment of Rheumatoid Arthritis Pain

Participants rated the severity of their rheumatoid arthritis pain in the past week by placing a vertical mark on a line with a range of 0 (no pain) to 100 mm (severe pain). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Participant's Global Assessment of Rheumatoid Arthritis Pain
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm8.0 ± 17.963.5 ± 14.33
Double Blind Week 10- Withdrawal Arm6.4 ± 19.059.3 ± 21.04
Double Blind Week 16- Tapering Arm17.8 ± 27.163.0 ± 12.48
Double Blind Week 16- Withdrawal Arm10.7 ± 18.93-0.6 ± 9.65
Double Blind Week 22- Tapering Arm10.4 ± 19.550.3 ± 7.82
Double Blind Week 22- Withdrawal arm4.0 ± 4.90-1.1 ± 11.20
Double Blind Week 28- Tapering arm8.3 ± 17.571.6 ± 9.83
Double Blind Week 28- Withdrawal Arm14.0 ± 24.59-1.4 ± 10.93
Double Blind Week 34- Tapering Arm11.6 ± 14.61-0.3 ± 7.61
Double Blind Week 34- Withdrawal Arm-3.5 ± 2.122.1 ± 8.40
Double Blind Week 40- Tapering Arm24.0 ± 32.67-0.5 ± 10.00
Double Blind Week 40- Withdrawal Arm-0.5 ± 20.51-0.9 ± 5.07
Flare Week 0- Tapering Arm24.4 ± 31.66—
Flare Week 0- Withdrawal Arm17.0 ± 19.38—
Flare Week 4- Tapering Arm9.0 ± 21.68—
Flare Week 4- Withdrawal Arm11.1 ± 17.46—
Flare Week 10- Tapering Arm7.5 ± 14.93—
Flare Week 10- Withdrawal Arm8.3 ± 9.60—
Flare Week 16- Tapering Arm8.0 ± 14.41—
Flare Week 16- Withdrawal Arm4.3 ± 6.32—
SecondaryMean Change From Double-blind Baseline in Physician's Global Assessment of Disease Activity

Physicians assessed participants' current rheumatoid arthritis disease activity at the time of the visit (independent of the participant's self-assessment) by placing a vertical mark on a line with a range of 0 (very low) to 100 mm (very high). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Physician's Global Assessment of Disease Activity
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm10.2 ± 19.541.3 ± 4.27
Double Blind Week 10- Withdrawal Arm1.6 ± 4.670.5 ± 4.74
Double Blind Week 16- Tapering Arm13.2 ± 21.480.9 ± 5.07
Double Blind Week 16- Withdrawal Arm5.0 ± 3.35-0.5 ± 2.98
Double Blind Week 22- Tapering Arm6.9 ± 14.830.9 ± 5.05
Double Blind Week 22- Withdrawal arm3.8 ± 2.870.4 ± 3.26
Double Blind Week 28- Tapering arm7.3 ± 16.511.7 ± 5.51
Double Blind Week 28- Withdrawal Arm10.0 ± 10.89-0.9 ± 2.74
Double Blind Week 34- Tapering Arm5.5 ± 12.270.8 ± 3.60
Double Blind Week 34- Withdrawal Arm0.0 ± 0.000.6 ± 4.13
Double Blind Week 40- Tapering Arm16.2 ± 26.911.0 ± 5.32
Double Blind Week 40- Withdrawal Arm19.5 ± 26.16-0.6 ± 2.42
Flare Week 0- Tapering Arm26.5 ± 23.28—
Flare Week 0- Withdrawal Arm17.4 ± 15.37—
Flare Week 4- Tapering Arm12.2 ± 17.06—
Flare Week 4- Withdrawal Arm9.3 ± 20.27—
Flare Week 10- Tapering Arm10.2 ± 13.82—
Flare Week 10- Withdrawal Arm12.9 ± 11.51—
Flare Week 16- Tapering Arm8.6 ± 12.48—
Flare Week 16- Withdrawal Arm7.6 ± 20.00—
SecondaryMean Change From Double-blind Baseline in Morning Stiffness Duration

The duration of morning stiffness was reported by participants as the average daily length during the past week in minutes (from time of awaking to time of maximal improvement). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · minutes
Mean Change From Double-blind Baseline in Morning Stiffness Duration
minutesFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm3.5 ± 17.331.8 ± 7.19
Double Blind Week 10- Withdrawal Arm1.1 ± 3.601.5 ± 5.97
Double Blind Week 16- Tapering Arm6.6 ± 24.412.3 ± 12.54
Double Blind Week 16- Withdrawal Arm9.2 ± 19.78-0.6 ± 5.05
Double Blind Week 22- Tapering Arm-1.6 ± 8.071.5 ± 9.67
Double Blind Week 22- Withdrawal arm1.0 ± 2.000.5 ± 3.70
Double Blind Week 28- Tapering arm2.6 ± 13.092.4 ± 10.53
Double Blind Week 28- Withdrawal Arm17.3 ± 28.810.0 ± 3.71
Double Blind Week 34- Tapering Arm0.6 ± 10.971.4 ± 8.86
Double Blind Week 34- Withdrawal Arm0.0 ± 0.00-1.1 ± 6.64
Double Blind Week 40- Tapering Arm2.0 ± 12.490.4 ± 9.33
Double Blind Week 40- Withdrawal Arm0.0 ± 0.00-0.2 ± 5.78
Flare Week 0- Tapering Arm13.5 ± 25.21—
Flare Week 0- Withdrawal Arm18.5 ± 26.25—
Flare Week 4- Tapering Arm25.0 ± 110.77—
Flare Week 4- Withdrawal Arm19.9 ± 26.51—
Flare Week 10- Tapering Arm8.1 ± 30.20—
Flare Week 10- Withdrawal Arm7.9 ± 9.72—
Flare Week 16- Tapering Arm17.3 ± 36.46—
Flare Week 16- Withdrawal Arm9.6 ± 20.65—
SecondaryMean Change From Double-blind Baseline in Morning Stiffness Severity

Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Morning Stiffness Severity
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm0.6 ± 1.510.4 ± 1.01
Double Blind Week 10- Withdrawal Arm0.4 ± 1.810.6 ± 1.29
Double Blind Week 16- Tapering Arm0.8 ± 1.730.3 ± 1.11
Double Blind Week 16- Withdrawal Arm0.7 ± 2.24-0.1 ± 1.04
Double Blind Week 22- Tapering Arm0.9 ± 1.270.2 ± 0.85
Double Blind Week 22- Withdrawal arm0.8 ± 0.960.4 ± 1.75
Double Blind Week 28- Tapering arm0.9 ± 1.690.2 ± 1.10
Double Blind Week 28- Withdrawal Arm1.3 ± 2.75-0.2 ± 0.87
Double Blind Week 34- Tapering Arm1.3 ± 1.710.1 ± 0.85
Double Blind Week 34- Withdrawal Arm0.0 ± 1.41-0.2 ± 1.08
Double Blind Week 40- Tapering Arm1.8 ± 2.520.1 ± 0.94
Double Blind Week 40- Withdrawal Arm-1.0 ± 1.41-0.4 ± 1.03
Flare Week 0- Tapering Arm1.6 ± 2.11—
Flare Week 0- Withdrawal Arm0.9 ± 1.96—
Flare Week 4- Tapering Arm0.8 ± 2.21—
Flare Week 4- Withdrawal Arm0.6 ± 1.72—
Flare Week 10- Tapering Arm0.6 ± 1.40—
Flare Week 10- Withdrawal Arm0.6 ± 1.27—
Flare Week 16- Tapering Arm0.6 ± 1.45—
Flare Week 16- Withdrawal Arm-0.1 ± 1.13—
SecondaryMean Change From Double-blind Baseline in Participant's Assessment of Sleep Disturbance

Participants rated the severity of their sleep disturbance in the past week by placing a vertical mark on a line with a range of 0 (sleep is no problem) to 100 mm (sleep is a major problem). Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Participant's Assessment of Sleep Disturbance
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm2.1 ± 15.370.0 ± 8.99
Double Blind Week 10- Withdrawal Arm-3.2 ± 29.390.8 ± 1.54
Double Blind Week 16- Tapering Arm10.2 ± 19.121.7 ± 15.96
Double Blind Week 16- Withdrawal Arm7.1 ± 22.421.1 ± 3.02
Double Blind Week 22- Tapering Arm8.2 ± 19.59-0.3 ± 10.91
Double Blind Week 22- Withdrawal arm8.3 ± 31.353.5 ± 8.70
Double Blind Week 28- Tapering arm1.8 ± 27.812.1 ± 12.67
Double Blind Week 28- Withdrawal Arm4.5 ± 19.82-1.0 ± 7.63
Double Blind Week 34- Tapering Arm5.6 ± 22.99-0.4 ± 11.48
Double Blind Week 34- Withdrawal Arm-0.5 ± 30.41-0.4 ± 2.77
Double Blind Week 40- Tapering Arm17.7 ± 34.04-0.2 ± 12.40
Double Blind Week 40- Withdrawal Arm-8.0 ± 15.56-1.0 ± 4.43
Flare Week 0- Tapering Arm18.9 ± 26.53—
Flare Week 0- Withdrawal Arm4.0 ± 14.61—
Flare Week 4- Tapering Arm4.9 ± 24.33—
Flare Week 4- Withdrawal Arm1.6 ± 10.05—
Flare Week 10- Tapering Arm0.2 ± 21.26—
Flare Week 10- Withdrawal Arm3.9 ± 12.98—
Flare Week 16- Tapering Arm2.3 ± 20.17—
Flare Week 16- Withdrawal Arm-7.3 ± 14.14—
SecondaryMean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Effectiveness Score

Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

Time frame:
At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Effectiveness Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 16- Tapering Arm-8.3 ± 35.300.2 ± 23.74
Double Blind Week 16- Withdrawal Arm2.8 ± 39.51-13.6 ± 43.84
Double Blind Week 28- Tapering arm-10.1 ± 24.28-3.8 ± 17.82
Double Blind Week 28- Withdrawal Arm-5.6 ± 45.59-17.2 ± 30.48
Double Blind Week 40- Tapering Arm-15.2 ± 33.53-4.4 ± 27.82
Double Blind Week 40- Withdrawal Arm-19.4 ± 27.50-16.2 ± 45.10
Flare Week 0- Tapering Arm-10.9 ± 39.82—
Flare Week 0- Withdrawal Arm-9.5 ± 38.05—
Flare Week 4- Tapering Arm-17.3 ± 40.07—
Flare Week 4- Withdrawal Arm-6.5 ± 48.23—
Flare Week 10- Tapering Arm-10.7 ± 44.07—
Flare Week 10- Withdrawal Arm7.9 ± 34.23—
Flare Week 16- Tapering Arm-7.5 ± 25.49—
Flare Week 16- Withdrawal Arm-16.7 ± 39.67—
SecondaryMean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Side Effects Score

Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

Time frame:
At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Side Effects Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 16- Tapering Arm-8.0 ± 17.25-0.5 ± 11.26
Double Blind Week 16- Withdrawal Arm9.4 ± 20.042.8 ± 9.42
Double Blind Week 28- Tapering arm-2.7 ± 12.281.1 ± 7.44
Double Blind Week 28- Withdrawal Arm14.1 ± 28.132.8 ± 9.42
Double Blind Week 40- Tapering Arm-2.3 ± 14.861.1 ± 11.61
Double Blind Week 40- Withdrawal Arm28.1 ± 39.772.8 ± 9.42
Flare Week 0- Tapering Arm-5.1 ± 15.96—
Flare Week 0- Withdrawal Arm2.7 ± 7.09—
Flare Week 4- Tapering Arm-5.0 ± 19.52—
Flare Week 4- Withdrawal Arm3.1 ± 7.65—
Flare Week 10- Tapering Arm-3.7 ± 13.90—
Flare Week 10- Withdrawal Arm2.7 ± 7.09—
Flare Week 16- Tapering Arm-2.0 ± 6.60—
Flare Week 16- Withdrawal Arm2.7 ± 7.09—
SecondaryMean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Convenience Score

Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

Time frame:
At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Convenience Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 16- Tapering Arm-0.2 ± 16.960.8 ± 13.45
Double Blind Week 16- Withdrawal Arm-4.9 ± 19.574.0 ± 10.86
Double Blind Week 28- Tapering arm0.0 ± 18.70-1.0 ± 15.47
Double Blind Week 28- Withdrawal Arm-4.2 ± 12.32-3.5 ± 13.21
Double Blind Week 40- Tapering Arm-4.0 ± 9.65-0.1 ± 16.50
Double Blind Week 40- Withdrawal Arm-16.7 ± 23.572.5 ± 18.32
Flare Week 0- Tapering Arm4.2 ± 12.53—
Flare Week 0- Withdrawal Arm-7.1 ± 14.60—
Flare Week 4- Tapering Arm4.4 ± 19.84—
Flare Week 4- Withdrawal Arm5.6 ± 18.92—
Flare Week 10- Tapering Arm1.2 ± 10.60—
Flare Week 10- Withdrawal Arm0.8 ± 16.49—
Flare Week 16- Tapering Arm1.6 ± 19.65—
Flare Week 16- Withdrawal Arm0.8 ± 20.89—
SecondaryMean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score

Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.

Time frame:
At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 16- Tapering Arm-11.6 ± 24.99-3.4 ± 17.91
Double Blind Week 16- Withdrawal Arm-2.7 ± 15.240.6 ± 22.69
Double Blind Week 28- Tapering arm-2.2 ± 12.70-5.7 ± 14.97
Double Blind Week 28- Withdrawal Arm5.4 ± 15.84-4.5 ± 25.81
Double Blind Week 40- Tapering Arm-3.2 ± 13.31-2.6 ± 15.10
Double Blind Week 40- Withdrawal Arm0.0 ± 10.10-3.2 ± 21.98
Flare Week 0- Tapering Arm-11.7 ± 27.58—
Flare Week 0- Withdrawal Arm-9.2 ± 25.66—
Flare Week 4- Tapering Arm-3.1 ± 20.32—
Flare Week 4- Withdrawal Arm-1.2 ± 24.08—
Flare Week 10- Tapering Arm-0.8 ± 13.77—
Flare Week 10- Withdrawal Arm-2.0 ± 18.77—
Flare Week 16- Tapering Arm-6.6 ± 24.20—
Flare Week 16- Withdrawal Arm-8.2 ± 16.72—
SecondaryMean Change From Double-blind Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment and Activity Impairment Scores

The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in rheumatoid arthritis consisting of 6 questions, based on participant recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.

Time frame:
At Weeks 4, 28, and 40 and Flare Weeks 0, 10, and 16
Reported as:
Mean · percent impairment
Mean Change From Double-blind Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment and Activity Impairment Scores
percent impairmentFlared ParticipantsNon-Flared Participants
Overall Work Impairment at Week 28- Tapering Arm15.0 ± 21.213.5 ± 10.68
Overall Work Impairment at Week 28- Withdrawal Arm0.00.6 ± 8.12
Activity Impairment at Week 28- Tapering arm5.0 ± 19.512.8 ± 13.43
Activity Impairment at Week 28- Withdrawal Arm10.0 ± 17.32-0.9 ± 7.01
Overall Work Impairment at Week 40- Tapering Arm—3.4 ± 18.78
Overall Work Impairment at Week 40- Withdrawal Arm—0.6 ± 8.12
Activity Impairment at Week 40- Tapering arm15.7 ± 9.760.5 ± 13.59
Activity Impairment at Week 40- Withdrawal Arm20.00.0 ± 6.32
Overall Work Impairment Flare Wk 0- Tapering Arm14.0 ± 27.02—
Overall Work Impairment Flare Wk 0- Withdrawal Arm5.0 ± 7.07—
Activity Impairment Flare Week 0- Tapering Arm25.9 ± 31.57—
Activity Impairment Flare Week 0- Withdrawal Arm8.0 ± 25.88—
Overall Work Impairment Flare Wk 10- Tapering Arm-0.2 ± 8.78—
Overall Work Impairment Flare W 10- Withdrawal Arm5.0 ± 7.07—
Activity Impairment Flare Wk 10- Tapering Arm6.5 ± 15.48—
Activity Impairment Flare W 10- Withdrawal Arm12.9 ± 13.80—
Overall Work Impairment Flare Wk 16- Tapering Arm10.0 ± 14.82—
Overall Work Impairment Flare W 16- Withdrawal Arm10.0 ± 10.00—
Activity Impairment Flare Wk 16- Tapering Arm11.0 ± 17.39—
Activity Impairment Flare Wk 16- Withdrawal Arm8.8 ± 11.26—
SecondaryMean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Physical Component Summary (PCS) Score

The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.

Time frame:
At Weeks 4, 28, and 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Physical Component Summary (PCS) Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 28- Tapering arm-2.9 ± 7.53-1.1 ± 4.18
Double Blind Week 28- Withdrawal Arm-1.9 ± 7.39-2.4 ± 3.97
Double Blind Week 40- Tapering Arm-5.5 ± 6.42-0.4 ± 5.53
Double Blind Week 40- Withdrawal Arm-1.6-2.1 ± 5.22
Flare Week 0- Tapering Arm-10.8 ± 10.85—
Flare Week 0- Withdrawal Arm-2.4 ± 10.81—
Flare Week 4- Tapering Arm-5.2 ± 8.37—
Flare Week 4- Withdrawal Arm-8.0 ± 7.35—
Flare Week 10- Tapering Arm-4.0 ± 7.22—
Flare Week 10- Withdrawal Arm-4.0 ± 4.57—
Flare Week 16- Tapering Arm-3.8 ± 7.38—
Flare Week 16- Withdrawal Arm-2.5 ± 2.80—
SecondaryMean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Mental Component Summary (MCS) Score

The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.

Time frame:
At Weeks 4, 28, and 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Mental Component Summary (MCS) Score
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 28- Tapering arm-5.5 ± 11.31-0.8 ± 6.02
Double Blind Week 28- Withdrawal Arm-5.2 ± 5.90-0.1 ± 7.20
Double Blind Week 40- Tapering Arm-3.5 ± 11.14-0.8 ± 5.89
Double Blind Week 40- Withdrawal Arm-8.5-0.4 ± 6.71
Flare Week 0- Tapering Arm-4.1 ± 11.43—
Flare Week 0- Withdrawal Arm0.4 ± 4.59—
Flare Week 4- Tapering Arm-2.0 ± 5.95—
Flare Week 4- Withdrawal Arm-0.5 ± 2.51—
Flare Week 10- Tapering Arm-1.1 ± 10.14—
Flare Week 10- Withdrawal Arm-0.4 ± 3.06—
Flare Week 16- Tapering Arm-4.0 ± 11.01—
Flare Week 16- Withdrawal Arm0.1 ± 2.55—
SecondaryMean Change From Double-blind Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale

The FACIT-Fatigue questionnaire is a participant questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A negative change from baseline indicates worsening.

Time frame:
At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · units on a scale
Mean Change From Double-blind Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale
units on a scaleFlared ParticipantsNon-Flared Participants
Double Blind Week 16- Tapering Arm-6.0 ± 9.80-1.5 ± 5.42
Double Blind Week 16- Withdrawal Arm-2.3 ± 3.39-1.9 ± 3.27
Double Blind Week 28- Tapering arm-3.5 ± 7.58-1.6 ± 5.60
Double Blind Week 28- Withdrawal Arm-4.3 ± 7.23-2.2 ± 4.67
Double Blind Week 40- Tapering Arm-6.4 ± 8.44-0.4 ± 4.00
Double Blind Week 40- Withdrawal Arm-2.5 ± 6.36-1.5 ± 4.78
Flare Week 0- Tapering Arm-7.4 ± 11.17—
Flare Week 0- Withdrawal Arm-3.6 ± 4.75—
Flare Week 4- Tapering Arm-3.8 ± 9.19—
Flare Week 4- Withdrawal Arm-4.7 ± 5.43—
Flare Week 10- Tapering Arm-3.9 ± 8.44—
Flare Week 10- Withdrawal Arm-2.4 ± 4.47—
Flare Week 16- Tapering Arm-4.5 ± 9.01—
Flare Week 16- Withdrawal Arm-1.7 ± 1.89—
SecondaryMean Change From Double-blind Baseline in Serum Levels of C-reactive Protein (CRP)

C-Reactive Protein (CRP; mg/L) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · mg/L
Mean Change From Double-blind Baseline in Serum Levels of C-reactive Protein (CRP)
mg/LFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm-7.9 ± 48.871.7 ± 12.92
Double Blind Week 10- Withdrawal Arm-0.2 ± 3.55-0.6 ± 2.53
Double Blind Week 16- Tapering Arm-7.4 ± 49.77-0.4 ± 4.26
Double Blind Week 16- Withdrawal Arm6.6 ± 12.26-0.1 ± 3.67
Double Blind Week 22- Tapering Arm3.6 ± 9.69-0.0 ± 5.43
Double Blind Week 22- Withdrawal arm0.6 ± 0.37-0.9 ± 3.38
Double Blind Week 28- Tapering arm0.5 ± 3.85-0.4 ± 4.65
Double Blind Week 28- Withdrawal Arm1.1 ± 1.342.5 ± 11.60
Double Blind Week 34- Tapering Arm3.2 ± 10.13-0.4 ± 4.41
Double Blind Week 34- Withdrawal Arm1.8 ± 1.890.3 ± 5.98
Double Blind Week 40- Tapering Arm1.0 ± 5.69-0.3 ± 4.18
Double Blind Week 40- Withdrawal Arm8.3 ± 11.60-0.1 ± 3.43
Flare Week 0- Tapering Arm-7.4 ± 54.12—
Flare Week 0- Withdrawal Arm5.4 ± 12.67—
Flare Week 4- Tapering Arm-8.5 ± 55.47—
Flare Week 4- Withdrawal Arm-1.3 ± 4.01—
Flare Week 10- Tapering Arm-9.5 ± 55.61—
Flare Week 10- Withdrawal Arm-0.6 ± 0.97—
Flare Week 16- Tapering Arm-9.1 ± 53.70—
Flare Week 16- Withdrawal Arm-0.8 ± 2.74—
SecondaryMean Change From Double-blind Baseline in Serum Levels of Erythrocyte Sedimentation Rate (ESR)

Erythrocyte sedimentation rate (ESR; mm/hour) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. Negative values indicate improvement from baseline.

Time frame:
From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Reported as:
Mean · mm/hour
Mean Change From Double-blind Baseline in Serum Levels of Erythrocyte Sedimentation Rate (ESR)
mm/hourFlared ParticipantsNon-Flared Participants
Double Blind Week 10- Tapering Arm4.1 ± 11.250.7 ± 5.22
Double Blind Week 10- Withdrawal Arm0.9 ± 9.24-1.5 ± 5.43
Double Blind Week 16- Tapering Arm4.6 ± 10.730.5 ± 5.82
Double Blind Week 16- Withdrawal Arm5.2 ± 15.23-0.3 ± 5.31
Double Blind Week 22- Tapering Arm3.5 ± 10.73-0.5 ± 7.38
Double Blind Week 22- Withdrawal arm2.8 ± 9.22-0.3 ± 4.22
Double Blind Week 28- Tapering arm3.4 ± 8.180.4 ± 6.93
Double Blind Week 28- Withdrawal Arm6.0 ± 10.101.0 ± 5.04
Double Blind Week 34- Tapering Arm4.8 ± 7.280.3 ± 7.57
Double Blind Week 34- Withdrawal Arm-5.0 ± 1.41-0.5 ± 5.94
Double Blind Week 40- Tapering Arm10.2 ± 13.221.4 ± 7.19
Double Blind Week 40- Withdrawal Arm-2.0 ± 5.664.7 ± 8.89
Flare Week 0- Tapering Arm10.4 ± 12.50—
Flare Week 0- Withdrawal Arm13.0 ± 11.90—
Flare Week 4- Tapering Arm7.2 ± 9.82—
Flare Week 4- Withdrawal Arm8.5 ± 9.52—
Flare Week 10- Tapering Arm5.8 ± 10.16—
Flare Week 10- Withdrawal Arm4.4 ± 6.91—
Flare Week 16- Tapering Arm8.0 ± 10.95—
Flare Week 16- Withdrawal Arm7.0 ± 14.40—

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug in the Double-blind Period (up to 50 weeks); for participants who experienced flare during the double-blind period, AEs were collected until 70 days after the last dose of study drug in the 16-week Open-label Rescue Period (up to 66 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 40 mg Eow0/146 (0%)4/146 (2.7%)11/146 (7.5%)
Adalimumab Tapering0/102 (0%)1/102 (1%)33/102 (32.4%)
Adalimumab Withdrawal Arm0/20 (0%)0/20 (0%)12/20 (60%)
Adalimumab 40 mg Eow Rescue Arm0/39 (0%)3/39 (7.7%)13/39 (33.3%)
Most frequent serious events
Most frequent serious events
EventAdalimumab 40 mg EowAdalimumab TaperingAdalimumab Withdrawal ArmAdalimumab 40 mg Eow Rescue Arm
RETINAL VEIN OCCLUSIONEye disorders0/1460/1020/201/39
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/1460/1020/201/39
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders0/1460/1020/201/39
BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1461/1020/200/39
ATRIAL FIBRILLATIONCardiac disorders1/1460/1020/200/39
PNEUMONIAInfections and infestations1/1460/1020/200/39
COMMINUTED FRACTUREInjury, poisoning and procedural complications1/1460/1020/200/39
TRANSIENT ISCHAEMIC ATTACKNervous system disorders1/1460/1020/200/39
Most frequent other events
Showing 10 of 22
Most frequent other events
EventAdalimumab 40 mg EowAdalimumab TaperingAdalimumab Withdrawal ArmAdalimumab 40 mg Eow Rescue Arm
NASOPHARYNGITISInfections and infestations4/14616/1024/204/39
INFLUENZAInfections and infestations0/1465/1022/200/39
LIMB INJURYInjury, poisoning and procedural complications0/1460/1022/201/39
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/1461/1020/203/39
ARTHRALGIAMusculoskeletal and connective tissue disorders0/1466/1020/201/39
URINARY TRACT INFECTIONInfections and infestations2/1460/1020/202/39
HEPATIC ENZYME INCREASEDInvestigations0/1460/1020/202/39
OEDEMA PERIPHERALGeneral disorders0/1460/1021/201/39
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations1/1463/1021/201/39
PHARYNGOTONSILLITISInfections and infestations0/1460/1021/200/39

Baseline characteristics

All Lead-in-Treated Subject population: participants who were enrolled in the study and received at least 1 dose of study drug during the Lead-in period

Age, Continuous
Age, Continuous(years)Adalimumab 40 mg Eow
Mean59.6 ± 10.30
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mg Eow
Female109
Male37
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adalimumab 40 mg Eow
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American2
White139
More than one race0
Unknown or Not Reported3
Tobacco Use
Tobacco Use(Participants)Adalimumab 40 mg Eow
Current22
Former46
Never76
Unknown2
Disease duration
Disease duration(years)Adalimumab 40 mg Eow
Mean12.9 ± 9.99
Duration of adalimumab therapy
Duration of adalimumab therapy(years)Adalimumab 40 mg Eow
Mean5.4 ± 3.27
Duration of remission
Duration of remission(years)Adalimumab 40 mg Eow
Mean2.2 ± 1.99
Previous treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)
Previous treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)(Participants)Adalimumab 40 mg Eow
Yes145
No1

5 further baseline measures are reported on the registry.

08

Study locations

70 sites
  • J Michael Grelier Research /ID# 149772
    Tuscaloosa, Alabama 35406, United States
  • Westlake Medical Research (WMR) Clinical Trials /ID# 155386
    Thousand Oaks, California 91360-3994, United States
  • University of Florida /ID# 144851
    Jacksonville, Florida 32209, United States
  • North Georgia Rheumatology Grp /ID# 155225
    Lawrenceville, Georgia 30045, United States
  • The Arthritis & Diabetes Clinic, Inc. /ID# 149017
    Monroe, Louisiana 71203, United States
  • Aa Mrc Llc /Id# 151933
    Grand Blanc, Michigan 48439, United States
  • North Mississippi Med Clinics /ID# 149443
    Tupelo, Mississippi 38801, United States
  • Montefiore Medical Center /ID# 155013
    Bronx, New York 10461, United States
  • Shanahan Rheuma & Immuno /ID# 148689
    Raleigh, North Carolina 27617, United States
  • Altoona Ctr Clinical Res /ID# 148448
    Duncansville, Pennsylvania 16635, United States
  • Low Country Rheumatology, PA /ID# 154198
    Summerville, South Carolina 29486, United States
  • West Tennessee Research Inst /ID# 148391
    Jackson, Tennessee 38305, United States
  • Arthritis Centers of Texas /ID# 152843
    Dallas, Texas 75246, United States
  • Royal Prince Alfred Hospital /ID# 154649
    Camperdown, New South Wales 2050, Australia
  • Optimus Clinical Research Pty. /ID# 133881
    Kogarah, New South Wales 2217, Australia
  • John Hunter Hospital /ID# 133884
    Newcastle, New South Wales 2305, Australia
  • Rheumatology Research Unit /ID# 133883
    Maroochydore, Queensland 4558, Australia
  • AKH Wien /ID# 133885
    Vienna, Wien 1090, Austria
  • St. Joseph's Healthcare /ID# 149233
    Hamilton, Ontario L8N 4A6, Canada
  • The Arthritis Program Res Grp /ID# 129056
    Newmarket, Ontario L3Y 3R7, Canada
  • Institut de Rhum. de Montreal /ID# 129055
    Montreal, Quebec H2L 1S6, Canada
  • Groupe de Recherche en Maladies Osseuses /ID# 129057
    Sainte-foy, Quebec G1V 3M7, Canada
  • CIUSSS de l'Estrie - CHUS /ID# 144839
    Sherbrooke, Quebec J1G 2E8, Canada
  • CHU de la miletrie /ID# 133928
    Poitiers, Poitou-Charentes 86021, France
  • CHU Amiens Picardie /ID# 144846
    Amiens CEDEX 1, Somme 80054, France
  • Hospital Louis Pasteur /ID# 134708
    Chartres, 28630, France
  • CHU de Grenoble - Albet Michal /ID# 135953
    Grenoble, 38043, France
  • Asklepios Klinik /ID# 129146
    Bad Abbach, 93077, Germany
  • Immanuel-Krankenhaus /ID# 129143
    Berlin-buch, 13125, Germany
  • Charité Universitätsmedizin Campus Mitte /ID# 129142
    Berlin, 10117, Germany
  • Krankenhaus Porz am Rhein /ID# 129147
    Cologne, 51149, Germany
  • Rheumaforschungszentrum II /ID# 148554
    Hamburg, 20095, Germany
  • Klinikum der Univ Munich /ID# 129144
    Munich, 80337, Germany
  • Rheumazentrum Ratingen /ID# 129148
    Ratingen, 40882, Germany
  • Rheumatologische Praxis /ID# 151979
    Rendsburg, 24768, Germany
  • University General Hospital "Attikon" /ID# 134709
    Athens, Attiki 12462, Greece
  • General Hospital of Athens /ID# 129202
    Athens, 11527, Greece
  • General UH of Heraklion /ID# 134712
    Heraklion, 71110, Greece
  • Budai Irgalmasrendi Korhaz /ID# 134714
    Budapest, 1023, Hungary
  • Orszagos Reumatologiai es Fizi /ID# 134710
    Budapest, 1023, Hungary
  • Debreceni Egyetem Klinikai Koz /ID# 134715
    Debrecen, 4032, Hungary
  • St Vincent's University Hosp /ID# 129210
    Dublin, D04 T6F4, Ireland
  • AP Romano Umberto I /ID# 132895
    Rome, Lazio 00161, Italy
  • A.O. Univ Consorziale Policlin /ID# 133932
    Bari, 70124, Italy
  • Azienda Istituto Gaetano Pini /ID# 132964
    Milan, 20122, Italy
  • Fondazione IRCCS Policlinico /ID# 133886
    Pavia, 27100, Italy
  • A.O.U.I. di Verona Policlinico /ID# 132973
    Verona, 37134, Italy
  • Jan van Breemen Instituut /ID# 133887
    Amsterdam, 1056 AB, Netherlands
  • Rijnstate Hospital /ID# 129206
    Arnhem, 6815 AD, Netherlands
  • Medisch Centrum Leeuwarden /ID# 133888
    Leeuwarden, 8934 AD, Netherlands
  • UMC Utrecht /ID# 132896
    Utrecht, 3584 CX, Netherlands
  • Hospital Parc de Salut del Mar /ID# 148670
    Barcelona, 08003, Spain
  • Hosp Sant J. Despi-Moises Brog /ID# 135368
    Barcelona, 08906, Spain
  • Hospital Universitario Basurto /ID# 135529
    Bilbao, 48013, Spain
  • Hosp Clinico Virgen Arrixaca /ID# 137020
    El Palmar, 30120, Spain
  • Hospital General Universitario Gregorio Maranon /ID# 133889
    Madrid, 28007, Spain
  • Hospital Universitario La Paz /ID# 135369
    Madrid, 28046, Spain
  • Hospital Univ De Mostoles /ID# 134489
    Mostoles, 28935, Spain
  • Complejo Hosp Santiago /ID# 133890
    Santiago de Compostela, 15706, Spain
  • Hosp General Univ de Valencia /ID# 134488
    Valencia, 46014, Spain
  • Akademiska Sjukhuset /ID# 148669
    Uppsala, Uppsala Lan 751 85, Sweden
  • Uppsala University Hospital /ID# 133891
    Uppsala, 75185, Sweden
  • Vastmanlands Sjukhus /ID# 133892
    Vasteras, 72189, Sweden
  • Whipps Cross Univ Hospital /ID# 133893
    London, London, City Of E11 1NR, United Kingdom
  • Guy's and St Thomas' NHS Found /ID# 132965
    London, London, City Of SE1 9RT, United Kingdom
  • Mid Essex Hospitals NHS Trust /ID# 151636
    Chelmsford, CM1 7ET, United Kingdom
  • Western General Hospital /ID# 132966
    Edinburgh, EH4 2XU, United Kingdom
  • Chapel Allerton Hospital /ID# 129208
    Leeds, LS7 4SA, United Kingdom
  • University Hospital Aintree /ID# 132980
    Liverpool, L9 7AL, United Kingdom
  • Queen Alexandra Hospital /ID# 132982
    Portsmouth, PO6 3LY, United Kingdom
09

References and documents

Publications

  • Emery P, Burmester GR, Naredo E, Sinigaglia L, Lagunes I, Koenigsbauer F, Conaghan PG. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study. Ann Rheum Dis. 2020 Aug;79(8):1023-1030. doi: 10.1136/annrheumdis-2020-217246. Epub 2020 May 13. PubMed 32404343 ↗
  • Emery P, Burmester GR, Naredo E, Zhou Y, Hojnik M, Conaghan PG. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA). BMJ Open. 2018 Feb 28;8(2):e019007. doi: 10.1136/bmjopen-2017-019007. PubMed 29490959 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in May 2018, 39 months.

Results were first posted in Jun 2019, 1 year 1 month after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 39 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2014
First posted
Jul 24, 2014
StartActual
Jan 5, 2015
Primary completionActual
May 3, 2018
CompletionActual
Aug 8, 2018
Results first posted
Jun 25, 2019
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02198651
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 24, 2014
Start date
Jan 5, 2015
Primary completion
May 3, 2018
Completion
Aug 8, 2018
Results posted
Jun 25, 2019
Last update
Jun 25, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion